Genome Medical, a nationwide telegenomics technology and services company, announced yesterday that it has expanded its clinical team by appointing clinical leads for each of its virtual specialty clinics in cancer, cardiovascular health, reproductive health, paediatrics and proactive health.
The company has named Alan Rope, MD as the new paediatric genetics lead. In his nearly 20 years of clinical experience, he served as a staff physician and medical geneticist at Kaiser Permanente Northwest and as an associate clinical professor of paediatrics at the University of Utah School of Medicine. The company has also chosen Catherine Fine, MS, CGC as its new cancer service lead. She is a board-certified genetic counsellor with nearly 15 years of clinical experience and she serves on the American Board of Genetic Counseling. She is a former clinical associate professor in the department of genetics at the University of North Carolina at Chapel Hill and previously founded Triangle Genetic Counseling.
Lindsay Meyers, MS, LCGC is named the cardiovascular genetics lead. She is a board-certified genetic counsellor specialising in cardiac genetics and has more than six years of experience in paediatric cardiology at Primary Children's Hospital in Salt Lake City. Betsy Swope, M.S, CGC has been chosen as the company's reproductive health lead. She is a board-certified genetic counsellor with more than 17 years of experience. She has worked at the University of Michigan, the University of North Carolina and Progenity Inc. The company has named Scott Weissman, MS, LCGC as its proactive health lead. He is a board-certified genetic counsellor with more than 15 years of experience in adult-onset genetic disorders and a focus on cancer genetics. He is a board member of the National Society of Genetic Counsellors. He previously worked at NorthShore University HealthSystem and several genetic testing companies.
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886